frontline rcc treatment selection: io/io versus io/tki
Published 7 months ago • 253 plays • Length 9:16Download video MP4
Download video MP3
Similar videos
-
7:57
patient selection for io/io versus io/tki in the frontline setting
-
6:45
the latest data on io/tki versus io/io in frontline rcc
-
8:06
panelists discuss their algorithm for treating frontline rcc
-
8:15
choosing an io/tki doublet for rcc patients: efficacy data, dosing, and more
-
10:04
drs. rini, plimack discuss the latest frontline io/tki data in rcc from 2023 asco® annual meeting
-
4:23
second-line treatment options for rcc
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab
-
8:50
comparison of frontline renal cell carcinoma treatment options
-
42:06
the uromigos: frontline therapy in rcc
-
9:01
longer-term follow-up on frontline io and tki studies and impacts to treatment selection
-
5:15
favorable-risk rcc: frontline vegf tki/io combinations
-
7:25
patient characteristics that drive treatment selection in renal cell carcinoma
-
4:57
review of the data of frontline treatment for non-clear cell kidney cancer
-
10:37
patient scenarios and treatment considerations in the adjuvant rcc setting
-
7:32
comparing combination treatment approaches in front-line advanced rcc
-
6:17
in rcc, what is the optimal treatment for intermediate/poor-risk disease?
-
9:28
rcc doublet considerations: immune-mediated toxicity, duration of treatment, and more
-
3:15
a novel approach: tki/i-o combinations in rcc
-
50:51
how to choose the right combo therapy - dr geynisman - 11/17/22